FDA approves launch of Titan’s Endoskeleton TL device for lateral spinal fusion

Comments · 37 Views

The Spinal Fusion market size is $7.51 billion in 2021. Spinal fusion is a surgical procedure that involves joining two vertebrae in the spine to form a single solid bone, with the involvement of certain devices, in order to relieve pain. Spinal fusion is performed by conventional and Mini

Titan Spinal Fusion devices Market has received approval from the Food and Drug Administration (FDA) of the United States to market its lateral approach spinal fusion solution, the Endoskeleton TL system.

The first device with surface technology, Endoskeleton TL, is designed to participate in the fusion process by producing an osteogenic response to the topography of the implant.

The company's roughened titanium surface technology is utilized in the lateral approach of the new device.

It has been demonstrated that the titanium surface technology increases the production of osteogenic and angiogenic factors, which are necessary for bone growth and fusion.

For more insights on the Spinal Fusion devices Market, Download a Free Sample

Bone graft packing, clear CT and MRI imaging, the desired bone graft loading, and the capacity to pack additional bone graft material within the device following implantation are all made possible by the device's large windows and large internal volumes.

At St. Mark's Hospital in Salt Lake City, orthopedic spine surgeon Kade Huntsman of Salt Lake Orthopaedic Clinic performed the first surgery with the Endoskeleton TL device in July 2014.

According to Huntsman, he was able to insert additional bone graft material into a lateral device for the first time after it had been implanted. The radiopaque nature of the TL made it simple to position the device in the desired location.

According to Huntsman, "I am excited to offer the TL to my patients requiring lateral interbody fusion, and the benefits of its surface technology and design features."

"The TL is the byproduct of a one-of-a-kind collaboration between academic biomaterial scientists, spine surgeons, and industry experts to create a truly differentiated lateral interbody device that is designed to benefit both patients and surgeons," reads the company's press release.
The company's implant surface technology is used in every Endoskeleton device. It is a one-of-a-kind combination of roughened topographies at the macro, micro, and cellular levels.

According to the company, the combination of surface topographies is intended to produce an optimal host-bone response and actively participate in the fusion process by encouraging the natural production of bone morphogenetic proteins (BMPs), promoting new bone growth, and presenting the possibility of a faster and more robust fusion.

Paul Slosar, chief medical officer of Titan Spine, stated: The lateral surgeon's arsenal has not included the ability to control cellular behavior and encourage bone growth in response to an interbody device until now.

"The TL is the result of a one-of-a-kind collaboration between academic biomaterial scientists, spine surgeons, and industry professionals to create a lateral interbody device that is truly unique and intended to benefit both patients and surgeons."

"Titan Spine now offers its surface technology and complete line of titanium devices for virtually all interbody fusion spine surgery procedures in the cervical and lumbar spine," the company says. "With the addition of the TL device."

Welcome to the new subscribers of the site. We are now doing some jobs on the site